E.U. Panel Backs Novartis' Mock-up Pandemic Flu Vaccine

by Medindia Content Team on  February 25, 2007 at 10:37 AM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

E.U. Panel Backs Novartis' Mock-up Pandemic Flu Vaccine
Europe's main medical regulator said it has adopted a positive opinion recommending the granting of a marketing authorization for Focetria, from Novartis AG (NVS) Vaccines and Diagnostics unit.

Focetria is a mock-up pandemic influenza vaccine, intended for the prevention of influenza during an officially declared pandemic situation, once the pandemic viral strain has been included. It is the second mock-up pandemic influenza vaccine to receive a positive opinion from the Committee.

Mock-up pandemic influenza vaccines are approved only for use in a declared pandemic influenza situation. The objective is to have a marketing authorization in place that can be changed quickly in the event of a pandemic to include the virus strain responsible, once it has been identified.

Source: Bio-Bio Technology
SRM

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Flu Swine Flu 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive